HEALTH

Chantal Sued for Allegedly Misleading Investors: In his federal court suit, a shareholder contends that the maker of an anti-wrinkle skin cream misled investors by overstating its financial performance. The suit claims more than half of Chantal Pharmaceutical Corp.’s revenue for the past five quarters was reported improperly. The suit, which seeks class-action status, claims the Los Angeles-based company executed a “fraudulent scheme” that overstated sales in the year ended June 30 by $3 million and in the quarter ended Sept. 30 by $10 million. The plaintiff in the suit is Marksman Partners, whose stake in Chantal was not disclosed. The suit also accuses the company and its chief executive, Chantal Burnison, of making false statements about its performance and financial condition. The company said it had no comment because it hadn’t seen the suit.